| Title |
Once-daily treatment of ADHD with guanfacine: patient implications
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, June 2008
|
| DOI | 10.2147/ndt.s1711 |
| Pubmed ID | |
| Authors |
Brandon C Strange |
| Abstract |
The standard of care for treating ADHD is to use a psychostimulant as the first line agent. Recent medical literature reports that approximately 70%-90% of patients with ADHD received some benefit from a stimulant medication. Even though psychostimulants have a high rate of efficacy, an estimated 30%-50% of children and adults may discontinue psychostimulants secondary to adverse effects or inadequate response. Guanfacine has been used for a number of years as an off label alternative to psychostimulants. This article reviews the current literature on the effectiveness of guanfacine in treating ADHD. It also introduces the preliminary data for guanfacine extended release and its effectiveness in decreasing the symptoms of ADHD. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Singapore | 1 | 17% |
| United States | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Brazil | 2 | 2% |
| Italy | 1 | 1% |
| India | 1 | 1% |
| Unknown | 75 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 21% |
| Student > Bachelor | 11 | 14% |
| Student > Master | 10 | 12% |
| Student > Doctoral Student | 9 | 11% |
| Other | 7 | 9% |
| Other | 18 | 22% |
| Unknown | 9 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 30% |
| Psychology | 15 | 19% |
| Neuroscience | 8 | 10% |
| Agricultural and Biological Sciences | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 11 | 14% |
| Unknown | 13 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 46. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2023.
All research outputs
#910,195
of 25,374,917 outputs
Outputs from Neuropsychiatric Disease and Treatment
#116
of 3,132 outputs
Outputs of similar age
#1,913
of 97,662 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#2
of 10 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,662 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.